Get In Touch

Thrombin is a serine protease enzyme encoded by a specific gene named F2 and is used to convert fibrinogen (soluble) into fibrin (insoluble). This conversion mimics the ending coagulation cascade step that includes the clotting mass which sticks to the wound surface and attains hemostasis and closing of open tissues. Human thrombin is a sterile solution, pH 6.8-7.2, comprising highly purified human thrombin for the activation of clotting. Human thrombin is used in several medical surgeries in the management of uncontrolled bleeding. It is also used in diagnostic centers and clinics in various applications such as coagulation assays, defibrination of blood or plasma, and clotting factor tests. R&D applications of human thrombin include several research activities such as protein-structure analysis, in vitro study, coagulation research, biochemical research, and medical research.

The global human thrombin market can be segmented on the basis of product type, dosage form, and end-user. Based on product type, it can be classified into three categories: alpha-thrombin, beta thrombin, and gamma-thrombin. Human alpha-thrombin is prepared from human prothrombin (homogeneous) by activation with Factor Xa, Factor Va, and phospholipid. SDS-PAGE is the preferred purification method. A minimum activity of around 2,200-2,700 NIH units/mg is shown by the activated human thrombin when compared to NIH standard thrombin. On the other hand, human β-thrombin and γ-thrombin are prepared from purified a-thrombin by limited proteolysis with TPCK-treated trypsin. Purity is measured by SDS-PAGE and activity is calculated using a fibrinogen clotting assay. Based on the dosage form, the global human thrombin market is segmented into solution form, powder form, patch, spray kits and others. On the basis of end-users, it is segmented into hospitals, diagnostic and clinics, ambulatory surgical centers, and academic and research institutes. Among the end-users, the hospital segment is anticipated to lead the market due to increase in the number of surgeries. The rising hemostatic use of thrombin-based products during surgeries has fuelled the demand for thrombin in the hospital segment.

The global human thrombin market is mainly driven by rising adoption in various research and diagnostic applications. Professionals have also observed a growth in human thrombin uptake, which is attributed to lesser post-operative complications and safer hemostatic condition. Human plasma is the only source for the production of human thrombin; thus, it carries a risk of transmitting infectious agents, such as viruses. Also, the presence of unknown infectious agents is also possible in the human thrombin. This is the major factor hindering the growth of the human thrombin market. In order to avoid such conditions, proper screening of the plasma donors for prior exposure to certain viruses is required.

Based on geography, the global human thrombin market has been segmented into major five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2016, North America and Asia Pacific accounted for the largest share of the human thrombin market, followed by Europe. The United States held a significant share of the human thrombin market in North America due to rise in the number of surgeries and increasing number of mobile surgical units and ambulatory centers. Asia Pacific is anticipated to show the fastest growth during the forecast period due to major contribution from countries such as Japan, India, and China. Japan dominated the market in Asia Pacific in 2016 due to the adoption of new thrombin therapies led by high awareness, significant health care spending in overall national budgets, early availability of advanced technologies, and extensive research activities. However, Latin America and Middle East & Africa are expected to witness moderate growth due to slow adoption of latest technologies. 

Some of the major players operating in the global human thrombin market are Baxter, AMRESCO Inc., BD Biosciences, Life Technologies Corporation, PromoCell GmbH, Sigma-Aldrich Corporation, Vitrolife AB, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, and Hualan Biological.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Human Thrombin Market

Pre Book